UNICYCIVE THERAPEUTICS, INC. Accrued Liabilities, Current
UNICYCIVE THERAPEUTICS, INC. (UNCY) had Accrued Liabilities, Current of $2.14 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $2.14M.
- 2026-03-31: Accrued Liabilities, Current $3.05M.
- 2025-12-31: Accrued Liabilities, Current $1.52M.
- 2025-09-30: Accrued Liabilities, Current $2.76M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $2.14M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.05M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.52M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.76M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.17M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.14M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.56M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.99M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.12M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $3.55M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $3.23M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.53M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.69M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.70M 10-Q · filed 2023-05-16 |
| 2022-12-31 | $2.24M 10-K · filed 2024-03-28 |
| 2022-09-30 | $3.06M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.93M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.66M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.21M 10-K · filed 2023-03-31 |
| 2021-09-30 | $633.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $658.00K 10-Q · filed 2021-08-16 |
| 2020-12-31 | $168.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |